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Gastric cancer (GC) is categorized as diffuse- and intestinal-type adenocarcinoma. Intesti-
nal-type GC is associated with chronic gastritis, atrophic gastritis (AG), and intestinal meta-
plasia (IM), precursors of dysplastic changes. Diffuse-type GC is generally known to
undergo de novo carcinogenesis and is not associated with chronic mucosal changes. How-
ever, clinically, AG and IM are frequently observed surrounding diffuse-type GC. This study
aimed to evaluate the role of AG and IM in diffuse-type GC.
Methods
We retrospectively reviewed the data of patients undergoing surgery for early GC. We
divided patients with diffuse-type GC into two groups according to the presence of AG and
IM based on Kyoto classification of gastritis. The clinicopathological characteristics were
compared between the groups.
Results
Among patients with diffuse-type GC, 52.5% patients had AG and 18.4% had severe AG.
With regard to IM, 42.1% patients had IM and 17.1% had severe IM. Diffuse-type GC com-
bined with severe AG or IM showed larger tumor size and higher submucosal invasion rate
than that without severe AG or IM. However, the lymph node metastasis (LNM) rate was not
significantly different between the two groups. In multivariate analysis, severe AG or IM was
not an independent risk factor for LNM.
Conclusions
Severe AG or IM surrounding diffuse-type gastric cancer suggests a collapse of normal
mucosal barriers and leads to the spread of cancer cells. Although the association between
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chronic mucosal changes and LNM is unclear, more caution is needed during endoscopy
especially for complete resection of diffuse-type GC with these features.
Introduction
Gastric cancer (GC) is classified into two major histological subtypes, diffuse-type and intesti-
nal-type adenocarcinoma, according to the Lauren classification [1]. The differences in epide-
miology, pathogenesis, and morphological appearance between these two GC types have been
widely accepted [1,2]. Diffuse-type GCs are often reported in young patients, are known to be
highly metastatic, and show more rapid progression and poor prognosis when compared with
intestinal-type GCs [3,4]. In terms of carcinogenesis, intestinal-type GC is more likely to be
associated with Helicobacter pylori (H. pylori) infection. The stepwise mucosal changes initi-
ated by H. pylori infection are considered to be a major step in the carcinogenic cascade of
intestinal-type GC [5,6], and atrophic gastritis (AG) and intestinal metaplasia (IM) are sug-
gested to be the typical chronic mucosal changes in this cascade [7–9]. AG is characterized by
multifocal loss of the original gastric glands, including mucus-secreting glands comprising
parietal and chief cells. AG has been suggested to be the first histopathological lesion in intesti-
nal-type GC [10,11]. IM is characterized by the appearance of glands with an intestinal pheno-
type that can be combined with multifocal atrophies involving the gastric mucosa. As atrophic
and metaplastic glands replace the normal gastric glands, the number of normal gastric glands
decreases, and precancerous processes such as dysplasia are initiated.
Carcinogenesis in diffuse-type GC is different from that in intestinal-type GC. A defined
series of preneoplastic mucosal changes or precancerous lesions are not usually found in dif-
fuse-type GC. Less well differentiated, non-glandular formations, with an occasional presence
of signet ring cells, are the pathological characteristics of diffuse-type GC [12]. However, it is
relatively common to find background mucosa in association with AG or IM surrounding dif-
fuse-type GC in a clinical setting during diagnostic endoscopy (Fig 1). Some diffuse-type GCs
are surrounded by these chronic mucosal changes, similar to that in intestinal-type GC.
Although pathological evaluation was considered to be the gold standard diagnostic modality
for AG and IM, recent studies have reported that endoscopic diagnosis of these chronic muco-
sal changes is also useful for identifying patients at risk of developing GC [13,14]. As chronic
mucosal changes account for a large proportion of cases of carcinogenesis in intestinal-type
GC, we wished to investigate the implications of chronic mucosal changes surrounding dif-
fuse-type GC noted during endoscopy. It is necessary to determine how these chronic mucosal
changes, which are precancerous lesions in intestinal-type GC, affect progression in diffuse-
type GC for further understanding of carcinogenesis in diffuse-type GC. Therefore, this study
aimed to identify the role of AG and IM surrounding diffuse-type GC.
Methods
Study design
This study evaluated 808 consecutive patients who underwent surgery for the treatment of
early gastric cancer (EGC) at Gangnam Severance Hospital, Seoul, Korea. We collected the
medical records and endoscopic images of patients who were diagnosed with EGC. Patients
without preoperative endoscopic images were excluded from this study. Furthermore, patients
in whom it was difficult to evaluate AG or IM owing to low resolution or insufficient images
were excluded. Finally, 451 patients with diffuse-type GC were enrolled. The intestinal-type
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GC group was randomly selected from the remaining study cohort to compare their clinico-
pathological features with those of the diffuse-type GC group. We analyzed the clinicopatho-
logical data and endoscopic images. This study protocol was approved by the Institutional
Review Board of Gangnam Severance Hospital (3-2019-0006) and was carried out in accor-
dance with the 1964 Declaration of Helsinki and its later amendments. Informed consent was
not required as this study was a retrospective analysis of existing administrative and clinical
data.
Endoscopic image review
All endoscopic images with unanalyzed clinicopathological data of patients enrolled during
the study period were collected and reanalyzed. AG and IM were categorized according to the
Kyoto classification of gastritis, proposed at the 85th Congress of the Japan Gastroenterological
Endoscopy Society for standardizing endoscopic findings of gastritis [15]. This classification
allows grading of endoscopically visible AG and IM. AG is assessed by the Kimura-Takemoto
classification (Close (C)-1, C-II, C-II; Open (O)-I, O-II, and O-III), and classified into three
grades (none, C0-C1; mild, CII-CIII; and severe, OI-OIII)[16]. IM is also classified into three
grades (none: none, mild: within the antrum, and severe: up to the corpus). In our study, two
experienced gastrointestinal endoscopists re-examined all endoscopic images in the same
manner and categorized AG and IM. They arrived at a consensus on this categorization
through regular meetings.
Clinicopathological evaluation
The medical records of patients, including their clinicopathological characteristics, were
reviewed by specialists who were blinded to the endoscopic findings. Pathological review was
Fig 1. Clinical cases of pathologically confirmed diffuse-type early gastric cancer (arrow). On endoscopic evaluation, (A) atrophic gastritis and (B) intestinal
metaplasia are observed in the surrounding mucosa.
https://doi.org/10.1371/journal.pone.0226427.g001
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performed based on reports of surgical specimens. The gross appearance of the tumors was
classified using the criteria of the Japanese Gastric Cancer Association, and the tumors were
classified into two groups accordingly. Protruding type (Type I) and superficially elevated type
(Type IIa) tumors were classified as elevated and the other types of tumor as non-elevated.
Longitudinal tumor location was defined as being in the upper (fundus, cardia, and upper
body), middle (mid-body, lower body, and the angle), and lower (antrum, prepylorus, and
pylorus) stomach. Tumor size was measured using the longest and shortest diameters. The
depth of tumor invasion was categorized as mucosal invasion (M), submucosal invasion of
500 μm or less from the muscularis mucosae (SM1), and submucosal invasion of more than
500 μm from the muscularis mucosae (SM2). Lymphovascular invasion (LVI), perineural inva-
sion (PNI), and lymph node metastasis (LNM) were also identified. The clinicopathological
features were compared between the severe AG or IM group and none-to-moderate AG or IM
group.
Statistical analysis
For categorical variables, a Pearson chi-square test was used. Student t-test was used to com-
pare the means of continuous variables, and continuous variables are presented as the
mean ± standard deviation (SD). Variables that were significant in univariate analysis were
subsequently tested by multivariate logistic regression analysis. Irrespective of the results of the
univariate analysis, variables that could potentially influence the results were included in mul-
tivariate analysis. For all comparisons, two-sided P-values <0.05 were considered statistically
significant. Statistical analyses were performed using SPSS version 18.0 (SPSS, Chicago, IL).
Results
Clinicopathological characteristics of intestinal-type and diffuse-type
gastric cancer
Table 1 summarizes the clinicopathological characteristics of intestinal- and diffuse-type GCs.
Diffuse-type GC, defined according to Lauren classification, included poorly differentiated
adenocarcinoma (n = 204, 45.3%), signet ring cell carcinoma (SRC) (n = 245, 54.3%), and
mucinous adenocarcinoma (n = 2, 0.4%). Patients with diffuse-type GC were younger and
included a higher proportion of females than patients with intestinal-type GC. Intestinal-type
GC showed a more elevated appearance and was more frequently located in the lower stom-
ach. Severe IM was identified significantly more often in intestinal-type GC patients (30.5% vs.
17.3%, P< 0.001). Among patients with diffuse-type GC, 52.5% had AG and 18.4% had severe
AG. In terms of IM, 42.1% patients had IM and 17.1% had severe IM in the group with dif-
fuse-type GC. Diffuse-type GC was more commonly found to be confined to the mucosal layer
in contrast to intestinal-type GC. LVI, PNI, and LNM rates were not significantly different
between the two types of GCs.
Comparison between diffuse-type gastric cancer with and without severe
atrophic gastritis
According to the severity of AG defined by Kyoto classification, patients with diffuse-type GC
were divided into the severe and non-severe AG groups. Table 2 shows the clinicopathological
features of the two groups. Diffuse-type GC with severe AG was frequently found in older
patients. The tumor size was larger (longest diameter, 3.671 ± 2.543 cm vs. 2.659 ± 1.762,
P = 0.001; shortest diameter, 2.551 ± 1.654 cm vs. 1.948 ± 1.740 cm, P = 0.006) and the rates of
SM invasion and LVI were higher in the severe AG group than in the non-severe AG group.
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However, the LNM rate was not significantly different between the groups. In multivariate
analysis, severe AG was not an independent risk factor for LNM (Table 3).
Comparison between diffuse-type gastric cancer with and without severe
intestinal metaplasia
Patients with diffuse-type GC were also divided according to the severity of IM as defined by
Kyoto classification into the severe and non-severe IM groups (Table 4). Upon comparing the
two groups, older age and male sex were commonly associated with severe IM. The tumor size
was larger in the severe IM group than in the non-severe IM group (longest diameter,
3.488 ± 2.657 cm vs. 2.725 ± 1.764 cm, P = 0.002; shortest diameter (cm), 2.449 ± 1.628 cm vs
1.973 ± 1.752 cm, P = 0.032). However, the depth of invasion, LVI, PNI, and LNM showed no
significant differences between the groups. In multivariate analysis, severe IM was not found
to be an independent risk factor for LNM (Table 3).
Table 1. Clinicopathological characteristics of intestinal- and diffuse-type gastric cancers.
Diffuse-type
GC (n = 451)
Intestinal-type
GC (n = 210)
P value
Age (years, mean ± SD) 56.88 ± 12.49 62.94 ± 10.83 <0.001
Male (n, %) 229 (50.8) 151 (71.9) <0.001
Pathological findings (n, %)
Well-differentiated adenocarcinoma 99 (47.1)
Moderately differentiated adenocarcinoma 111 (52.9)
Poorly differentiated adenocarcinoma 204 (45.3) -
Signet ring cell carcinoma 245 (54.3) -
Mucinous adenocarcinoma 2 (0.4) -
Kyoto classification 0.659
Atrophic gastritis (n, %) 0.528
None to mild 368 (81.6) 167 (79.5)
Severe 83 (18.4) 43 (20.5)
Intestinal metaplasia (n, %) <0.001
None to mild 373 (82.7) 146 (69.5)
Severe 78 (17.3) 64 (30.5)
H. pylori infection (n, %) 206 (45.8) 152 (73.4) <0.001
Longitudinal location (n, %) 0.009
Lower 272 (60.3) 150 (71.4)
Mid 141 (31.3) 42 (20.0)
Upper 38 (8.4) 18 (8.6)
Gross appearance (n, %) <0.001
Elevated 67 (14.9) 62 (29.5)
Non-elevated 384 (85.1) 148 (70.5)
Depth of invasion (n, %) 0.031
M 259 (57.4) 99 (47.1)
SM1 (�500 μm) 40 (8.9) 28 (13.3)
SM2 (�500 μm) 152 (33.7) 83 (39.5)
LVI (n, %) 55 (12.2) 16 (7.6) 0.075
PNI (n, %) 15 (3.3) 5 (2.4) 0.509
LNM (n, %) 38 (8.4) 9 (4.3) 0.054
H. pylori, Helicobacter pylori; M, mucosa; SM, submucosa; LVI, lymphovascular invasion; PNI, perineural invasion; LNM, lymph node metastasis; GC, gastric cancer
https://doi.org/10.1371/journal.pone.0226427.t001
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Age (years, mean ± SD) 53.17 ± 12.17 63.29 ± 10.51 <0.001
Male (n, %) 183 (49.7) 46 (55.4) 0.349
H. pylori infection (n, %) 125 (33.9) 27 (32.5) 0.307
Longitudinal location (n, %) 0.354
Lower 219 (59.5) 53 (63.9)
Mid 120 (32.6) 21 (25.3)
Upper 29 (7.9) 9 (10.8)
Gross appearance (n, %) 0.362
Elevated 52 (14.1) 15 (18.1)
Non-elevated 316 (85.9) 68 (81.9)
Depth of invasion (n, %) 0.001
M 225 (61.1) 34 (41.0)
SM 143 (38.9) 49 (59.0)
Size (cm, mean ± SD)
Longest diameter 2.659 ± 1.762 3.671 ± 2.543 0.001
Shortest diameter 1.948 ± 1.740 2.551 ± 1.654 0.006
LVI (n, %) 34 (9.3) 21 (25.3) <0.001
PNI (n, %) 10 (2.7) 5 (6.0) 0.129
LNM (n, %) 30 (8.2) 8 (9.6) 0.660
H. pylori, Helicobacter pylori; M, mucosa; SM, submucosa; LVI, lymphovascular invasion; PNI, perineural invasion; LNM, lymph node metastasis
https://doi.org/10.1371/journal.pone.0226427.t002
Table 3. Multivariate analysis of clinicopathological characteristics associated with LNM in diffuse-type gastric
cancer.
Odds ratio (95% confidence interval) P value
Severe atrophic gastritis 0.069
No Reference
Yes 0.381 (0.134–1.080)





>2 cm 2.985 (1.165–7.647)









LNM, lymph node metastasis; M, mucosa; SM, submucosa; LVI, lymphovascular invasion; PNI, perineural invasion
https://doi.org/10.1371/journal.pone.0226427.t003
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Discussion
In accordance with previous studies, diffuse-type GC was associated with younger age and
female sex compared with intestinal-type GC in our study [17,18]. Older patients and IM were
significantly more common among those with intestinal-type GC. AG was also more fre-
quently observed in intestinal-type GC, although the difference was not statistically significant.
Intestinal-type GC showed more elevated lesions and was commonly located at a lower loca-
tion, which is in accordance with previous findings [17]. Our study was unable to demonstrate
a higher rate of SM invasion in diffuse-type GC than in intestinal-type GC. A possible explana-
tion for this might be the relatively higher proportion (54.3%) of SRC cases in our study,
which is known to be associated with a low incidence of SM invasion [18].
Severe AG and IM were noted in approximately 20% patients with diffuse-type GC during
diagnostic endoscopy. We limited the comparison to that between severe AG or IM and others
to minimize interobserver or intraobserver variation during endoscopic evaluation of AG or
IM. Older patients more commonly showed these chronic mucosal changes. Chronic mucosal
changes resulting from H. pylori infection are involved in the carcinogenesis of intestinal-type
GC. In this study, patients with intestinal-type GC showed a higher infection rate of H. pylori
compared to those with diffuse-type GC. H. pylori infection induces a chronic inflammatory
reaction in the gastric mucosa, which causes atrophic changes or transformation of the glandu-
lar gastric epidermis to intestinal-type epithelium. The alkaline environment caused by these
chronic mucosal changes facilitates the proliferation of H. pylori, which in turn leads to cell
turnover increase and accumulation of mitotic errors resulting in cancerous changes of the
gastric mucosa [19–21]. The higher infection rate of H. pylori in intestinal-type GC is thought








Age (years, mean ± SD) 53.83 ± 12.43 60.73 ± 11.32 <0.001
Male (n, %) 178 (47.8) 49 (63.6) 0.012
H. pylori infection (n, %) 127(34.0) 25 (32.1) 0.191
Longitudinal location (n, %) 0.648
Lower 226 (60.5) 46 (58.4)
Mid 114 (3.6) 27 (35.1)
Upper 33 (8.9) 5 (6.5)
Gross appearance (n, %) 0.858
Elevated 55 (14.8) 12 (15.6)
Non-elevated 318 (85.2) 66 (84.4)
Depth of invasion (n, %) 0.263
M 219 (58.9) 40 (51.9)
SM 154 (41.1) 38 (59.0)
Size (cm, mean ± SD)
Longest diameter 2.725 ± 1.764 3.488 ± 2.657 0.002
Shortest diameter 1.973 ± 1.752 2.449 ± 1.628 0.032
LVI (n, %) 40 (10.8) 15 (19.5) 0.054
PNI (n, %) 12 (3.2) 3 (3.9) 0.766
LNM (n, %) 29 (7.8) 9 (11.7) 0.264
H. pylori, Helicobacter pylori; M, mucosa; SM, submucosa; LVI, lymphovascular invasion; PNI, perineural invasion; LNM, lymph node metastasis
https://doi.org/10.1371/journal.pone.0226427.t004
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to be associated with this carcinogenic cascade. Diffuse-type GC has widely been believed to
arise from the mucosa without chronic mucosal changes, and shows no precancerous lesions.
Therefore, endoscopists tend to presumably diagnose cancerous lesions with background
chronic mucosal changes as intestinal-type GC based on diagnostic endoscopy. However, our
study showed that cases with diffuse-type GC arising from background mucosa with AG or IM
are more common than expected. A previous Japanese study demonstrated that endoscopic
findings in patients with undifferentiated adenocarcinoma diagnosed according to the Japa-
nese Classification of Gastric Carcinoma (14th edition) showed the presence of severe AG in
21.8% and severe IM in 19.4% patients [22]. They also suggested ambiguous glandular duct
architecture, venous invasion, and reddish lesions as characteristic endoscopic findings in
undifferentiated adenocarcinomas with severe AG [22]. Another study evaluating the back-
ground mucosa in patients with GC during diagnostic endoscopy found that open-type AG
according to the Kimura-Takemoto classification is present in many patients with undifferen-
tiated adenocarcinoma [23]. Our findings support the results of these previous studies. The
incidence of severe AG and IM in diffuse type-GC may be explained by the increasing preva-
lence of AG and IM with age, as well as H. pylori infection [24], as the mean age of patients
with severe AG or IM was higher than that of patients with non-severe AG or IM in our study.
Thus, not only intestinal-type GC but also diffuse-type GC can arise from background mucosa
with severe AG or IM. Therefore, a more careful and non-prejudiced approach is needed for
evaluating lesions with these chronic mucosal changes during endoscopy. However, there is
no previous study on whether these chronic mucosal changes are associated with aging or play
any meaningful role in diffuse-type GC. Thus, we attempted to investigate the role of chronic
mucosal changes surrounding diffuse-type GC in this study.
Compared with the non-severe AG group, the severe AG group showed a larger tumor size
and higher SM invasion and LVI rates. The tumor size was also larger in the severe IM group
compared to that in the non-severe IM group. A previous study demonstrated that the tumor
size is larger in patients with undifferentiated-type GC with severe AG than in those with
undifferentiated-type GC with mild-to-moderate AG [22]. The reason for the increase in
tumor size when associated with severe AG or IM is uncertain. However, cancer cells seem to
spread more easily in both horizontal and vertical directions when the background mucosa
shows AG or IM. A possible explanation for these pathological findings is assumed to be the
fact that the surrounding mucosa acts as a mechanical barrier to the spread of cancer cells in
diffuse-type GC.
In terms of the barrier function of the mucosa, previous studies have reported that a diverse
group of transmembrane proteins maintain the epithelial barrier function against pathogens.
Tight junction proteins are present on the apical end of the lateral membrane surface in
columnar epithelial cells and function as a barrier [25,26]. Although scarce data exist on the
physiology or function of this barrier, barrier dysfunction is suggested to be a risk factor for
cancer development in association with H. pylori infection [27]. The concept of mechanical
barriers related to the spreading of cancer cells was reported in a study on SRC [28]. The sur-
rounding mucosal pattern differs according to the manner in which the tumor spreads, and
cells in SRC tend to spread diffusely into the subepithelial area in the presence of background
mucosa with AG or IM. The authors further suggested that if the mechanical barrier repre-
sented by the surrounding mucosa is weak, such as in cases with AG or IM, cancer cells tend
to spread sporadically or diffusely into the deeper layers of the mucosa. In addition, the status
of the surrounding mucosa is suggested to be a predictive factor of intramucosal spreading pat-
terns in SRC. In line with this, our study demonstrated that the disrupted mucosal barriers, as
seen in cases with severe AG or IM, allow the cancer cells in diffuse-type GC to spread more
easily in both horizontal and vertical directions. The fact that metachronous cancer occurs
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more frequently in cases with diffuse-type GC is also thought to be associated with AG or IM
[29]. AG or IM, which suggests weakening of the mechanical barrier, can facilitate sporadic
spreading of cancer cells. Thus, more careful assessment is required in patients with diffuse-
type GC with severe AG or IM, especially when performing endoscopic resection as well as
diagnostic endoscopy.
One interesting finding of our study is that the LNM rate showed no significant differences
between the severe AG or IM and non-severe groups. A previous study investigating SRC
showed similar results to those shown in our study [28]. Although the weakening of the
mechanical barrier induced by AG or IM combined with diffuse-type GC is associated with
the spreading of cancer cells into the mucosa and allows the tumor to increase in size or show
LVI, it does not seem to have a significant effect on the prognosis of patients. Severe AG or IM
affects the tumor size and SM invasion; however, it was not an independent risk factor of
LNM. Although the exact reason for this finding remains unclear, a possible explanation for
this might be that AG and IM themselves do not directly affect LNM, but the risk of LNM is
increased owing to changes in the spreading pattern of cancer cells caused by these chronic
mucosal changes. In other words, AG or IM in diffuse-type GC do not influence the aggressive
behavior of cancer, but rather provide an environment in which the cancer cells spread more
aggressively. Validation of our findings with a large-scale study is needed to gain further
insight.
A previous Japanese study demonstrated that most intestinal-type GCs occur in association
with severe AG or IM, whereas diffuse-type GCs occur predominantly at the atrophic border
which is characterized by active inflammation. These authors suggested that active inflamma-
tion may cause DNA damage in gastric epithelial cells [30]. Several studies have also suggested
genetic abnormalities in cell adhesion factors, rather than chronic mucosal changes, as the
cause of diffuse-type GC [31–34]; our study supports this notion. In contrast to its role as a
precancerous lesion in the carcinogenesis of intestinal-type GCs, AG or IM in diffuse-type
GCs may play a role related to the mechanical barrier function of the mucosa, which is not
associated with carcinogenesis.
This study has several limitations. Firstly, it was a retrospective, single-center study. Sec-
ondly, interobserver bias may exist given that this study was performed based on a review of
endoscopic images. However, endoscopists applied the same criteria for the endoscopic review
and reached consensus through periodic meetings. To the best of our knowledge, this is the
first study to evaluate the role of AG or IM in diffuse-type GC. Further large-scale studies are
needed to validate our results.
In conclusion, AG or IM surrounding diffuse-type GC suggests the destruction of the nor-
mal mechanical barrier that prevents the spread of cancer cells. Although these chronic muco-
sal changes may not play a role in the process of carcinogenesis in diffuse-type GC, in contrast
to their role in intestinal-type GC, more careful assessment is needed in cases with diffuse-type
GC during endoscopy, especially in order to achieve a complete endoscopic resection.
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